ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

NCT05025800 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Aggressive B-Cell Non-Hodgkin Lymphoma
Ann Arbor Stage III Grade 2 Follicular Lymphoma
Ann Arbor Stage III Grade 3 Follicular Lymphoma
Ann Arbor Stage III Marginal Zone Lymphoma
Ann Arbor Stage IV Grade 1 Follicular Lymphoma
Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Ann Arbor Stage IV Marginal Zone Lymphoma
Composite Lymphoma
Indolent B-Cell Non-Hodgkin Lymphoma
Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Refractory Follicular Lymphoma
Refractory Grade 3b Follicular Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Mantle Cell Lymphoma
Refractory Marginal Zone Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Richter Syndrome

Interventions

DRUG: CD47 Antagonist ALX148
DRUG: Lenalidomide
BIOLOGICAL: Rituximab

Sponsor

M.D. Anderson Cancer Center